Table 4. . Outcomes of ipilimumab-treated patients who received pembrolizumab.

Pt#	Best response to ipilimumab	Time (days) between PD and pembrolizumab	Best response to pembrolizumab	Total cycles received	PFS (months)†	OS (months)†
1	PD	29	PR	41, ceased due to PD	36.9	44.7
2	PD	187‡	CR	33, ceased due to CR/AE	NR, 47.4+	NR, 47.4+
9	PD	15	PD	4, ceased due to PD	2.3	5.3
10	PR	34	PD	2, ceased due to PD	1.8	3.9
12	Not assessed	21 (planned switch)	PD	3	3.2	9.6
13	PD	39	SD	20+, ongoing	NR, 13.5+	NR, 13.5+

^†From time of initiating pembrolizumab.

^‡This patient received chemotherapy with four cycles of carboplatin/paclitaxel and had a sustained PR of 5 months.

AE: Adverse event; CR: Complete response; NR: Not reached; OS: Overall survival; PD: Progressive disease; PFS: Progression-free survival; PR: Partial response; Pt#: Patient number; SD: Stable disease.